Heart failure-related mortality among older adults improved from 1999 to 2012, but then things changed considerably over the next several years. Researchers explored the latest data at length, sharing their findings in JACC: Heart Failure.

The FDA has been busy this month. Review some of the biggest FDA-related stories of October, including big news from scPharmaceuticals, Abiomed, Bristol Myers Squibb and MedAlliance, in our monthly roundup. 

The device includes dual-sensor technology, an 11 French indwelling catheter and a flexible cannula.

“Once the study begins, it will likely be one of the largest heart pacing clinical trials happening in the world over the next few years," one specialist said. 

"We expected to see a significant improvement in outcomes for patients with severe or rapidly progressing cardiogenic shock who underwent early ECMO treatment," one specialist said. 

While some heart failure medications are less effective in patients with concomitant atrial fibrillation, new research suggests that is not the case for dapagliflozin.